A. Boonstra (Amsterdam, The Netherlands), L. Nicod (Lausanne, Switzerland)
Late-breaking abstract: Short term improvement in 6 minute walk distance predicts long term survival in incident idiopathic pulmonary arterial hypertension. Results from the Pulmonary Hypertension Registry of the United Kingdom and Ireland
Y. Ling, M. Johnson, D. Kiely, R. Condliffe, C. Elliot, S. Gibbs, L. Howard, J. Pepke-Zaba, K. Sheares, P. Corris, A. Fisher, J. Lordan, S. Gaine, G. Coghlan, J. Wort, M. Gatzoulis, A. Peacock (Clydebank, Sheffield, London, Papworth, Newcastle, United Kingdom; Dublin, Ireland)
|   |
Comparison of hemodynamic effects of inhaled nitric oxide (iNO) and inhaled epoprostenol (iEPO) in patients with pulmonary hypertension (PH)
S. A. DeSouza, K. D. Sagliani, I. R. Preston, K. E. Roberts, A. Shah, N. S. Hill (Boston, United States Of America)
| |
Pulmonary artery diameter and pulsatility did not decrease after vasodilator therapy lasting two years
P. Bracciale, F. Valerio, S. Bellanova, G. Valerio, L. Mangiacotti, A. G. D‘Agostino (San Pietro Vernotico, Lecce, Brindisi, Italy)
| |
The use of perioperative intravenous sildenafil in patients with mitral valve disease and co-existent pulmonary hypertension during cardiac surgery
B. P. Madden, S. Sharma, E. Holden, Y. Looney, S. N. Fletcher, A. Sheth (London, United Kingdom)
| |
Current epoprostenol use in patients with severe pulmonary hypertension (PH): Data from the French PH registry
E. Bergot, O. Sitbon, V. Cottin, A. Yaici, G. Prévot, L. Rottat, V. Gressin, M. Humbert, G. Simonneau (Caen, Clamart, Lyon, Toulouse, Paris, France)
| |
Effectiveness of ²Korargin² in the therapy of pulmonary arterial hypertension in patients with systemic lupus erythematosus
O. Yakovleva, A. Klekot (Vinnitsa, Ukraine)
| |
Impact of functional class change on survival in patients with pulmonary arterial hypertension in the REVEAL registry
R. Barst, D. Miller, F. Beery, M. McGoon (New York, San Francisco, Rochester, United States Of America)
| |
Inhaled treprostinil therapy in patients with pulmonary hypertension and parenchymal lung disease
A. Schiro, A. Waxman (Boston, United States Of America)
| |
Parenteral treprostinil for significant pulmonary arterial hypertension associated with pulmonary fibrosis: A safety study
R. Saggar, D. Khanna, J. Belperio, S. Shapiro, R. Saggar (Los Angeles, United States Of America)
| |
Cardiotonic agents affect pulmonary vessels in precision-cut lung slices (PCLS)
A. D. Rieg, R. Rossaint, S. Uhlig, C. Martin (Aachen, Germany)
| |
Stability and microbial properties of reconstituted and diluted epoprostenol with expanded stability
O. Lambert, D. Bandilla, R. Iyer, L. Witchey-Lakshmanan, N. Palepu (Allschwil, Switzerland; Cherry Hill, Piscataway, Amherst, United States Of America)
| |
Cardiac output measured by rebreathing nitrous oxide for the follow-up of patient with pulmonary hypertension
G. Deboeck, R. McKenzie Ross, J. Pepke-Zaba (Papworth, United Kingdom)
| |
Use of non invasive gas exchange to track pulmonary vascular responses to exercise in heart failure
P. Woods, B. Taylor, T. Olson, B. Johnson (Rochester, United States Of America)
| |
Is flying safe for individuals with pulmonary arteriovenous malformations and hereditary haemorrhagic telangiectasia? A questionnaire-based study
C. Mason, C. Shovlin (London, United Kingdom)
| |
Is there an association between hyperthyroidism and PAH and, if yes, is pulmonary pressure decreasing after hyperthyroidism treatment?
A. Al Husseini, S. Mizuno, J. Arroyo, N. Voelkel, D. Kraskauskas, H. Bogaard (Richmond, United States Of America)
| |
Immunosuppression in systemic lupus erythematosus associated pulmonary arterial hypertension (SLE-APAH): Improvement in exercise and functional capacity
Y. Sung, J. Ashouri, R. Zamanian, L. Chung (Stanford, Palo Alto, United States Of America)
| |
Monitoring of liver function in patients with pulmonary hypertension treated with endothelin receptor antagonists: The value of a novel monitoring system
C. Blewett, E. Lunn, D. Kiely, L. Martin, J. Hurdman, N. Hamilton, I. Armstrong, P. Septon, J. Wilkinson, R. Condliffe, C. Elliott (Sheffield, United Kingdom)
| |
Is there a link between long-term endothelial receptor antagonists therapy and carcinogenesis in PAH: A case series?
H. Qureshi, Z. Safdar (Houston, United States Of America)
| |